Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Genitourinary Cancers
•
Prostate Cancer
•
Medical Oncology
•
Hospital Medicine
How would you approach hypercalcemia in a patient with metastatic prostate cancer with extensive bone metastasis?
Related Questions
What duration androgen deprivation do you recommend with salvage pelvic radiotherapy for pelvic node relapse after prostatectomy?
Would you prescribe semaglutide for weight gain from androgen deprivation therapy for prostate cancer?
What are your top takeaways from ASCO GU 2025?
How would you approach de novo metastatic castrate sensitive prostate cancer with extensive locoregional spread causing rectal compression, retroperitoneal lymphadenopathy, and PSA >3000 but no visceral or bone metastases?
Given results of the RADICALS trials, is LT-ADT standard of care for salvage prostate RT?
In which patients are referring for focal gland therapy for localized prostate cancer?
How do you manage critically ill poor risk mixed germ cell tumor patients presenting de novo with extensive lung metastases and severe respiratory failure?
Do you add ADT to RT for a patient with intermediate-risk prostate cancer with discordant Decipher and ArteraAI results?
How would you approach patients with high-risk localized prostate cancer (per STAMPEDE criteria) receiving RT and concurrent ADT but are unable to tolerate abiraterone secondary to toxicities?
How do you manage PSA progression while a patient is on xofigo or pluvicto?
